American Journal of Epidemiology Vol. 134, No. 12: 1386-1395
Copyright © 1991 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
Breast Cancer Risk after Estrogen Replacement Therapy: Results from the Toronto Breast Cancer Study
1Slone Epidemiology Unit School of Public Health Boston University School of Medicine Brookline MA
2Division of Epidemiology and Statistics Ontario Cancer Treatment Research Foundation Toronto Ontario Canada
3Health Research Associates Jamaica Plain MA
Reprint requests to Dr. Julie R. Palmer, Slone Epidemiology Unit 1371 Beacon Street, Brookline, MA 02146
The authors examined noncontraceptive estrogen use in relation to breast cancer risk in women under age 70 in a case-control study conducted in Toronto, Canada. Cases were 607 women with incident primary breast cancer, identified at the time of hospitalization for treatment. They were compared to 1,214 controls matched to the cases on neighborhood and decade of age. Information was obtained through personal interviews conducted in the subjects' homes. Most estrogen users had taken conjugated estrogens, and only 7% had also taken progestogens. Compared with never use, the estimated relative risk for ever use of unopposed conjugated estrogens was 0.9 (95% confidence interval (Cl) 0.6–1.2) after allowance for multiple confounding factors. Relative risk estimates for most duration categories were close to 1.0; the estimate for the longest duration category, 
15 years of use, was elevated (1.5, 95% Cl 0.6–3.8), but there was not a significant trend with increasing duration. The estimate for current use or use that ended less than 12 months before interview and had lasted for at least 5 years was 0.9 (95% Cl 0.4–1.9). The results provide evidence against an increase in risk among women who used unopposed conjugated estrogens for less than 15 years and for recent users; for women with durations of at least 15 years, an increase could not be ruled out.Am J Epidemiol 1991;134:1386–95
breast neoplasms; estrogen replacement therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Zhang, J. E. Manson, K. M. Rexrode, N. R. Cook, J. E. Buring, and I-M. Lee Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer Am. J. Epidemiol., March 1, 2007; 165(5): 524 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials Hum. Reprod. Update, November 1, 2005; 11(6): 561 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chen, N. S. Weiss, P. Newcomb, W. Barlow, and E. White Hormone Replacement Therapy in Relation to Breast Cancer JAMA, February 13, 2002; 287(6): 734 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Al-Azzawi The menopause and its treatment in perspective Postgrad. Med. J., May 1, 2001; 77(907): 292 - 304. [Full Text]
|
|
|
|
 |
|
 R. J. Santen, J. Pinkerton, C. McCartney, and G. R. Petroni Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 16 - 23. [Full Text]
|
|
|
|
|
|
T. L. Bush and M. K. Whiteman Hormone Replacement Therapy and Risk of Breast Cancer JAMA, June 9, 1999; 281(22): 2140 - 2141. [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Gambrell Jr Hormone Replacement Therapy and Breast Cancer Risk Arch Fam Med, June 1, 1996; 5(6): 341 - 348. [Abstract] [PDF]
|
|
|
|
|
|
R. E. Harris, K. K. Namboodiri, W. B. Farrar, S. M. Solano, and E. L. Wynder Hormone Replacement Therapy and Breast Cancer Risk JAMA, April 17, 1996; 275(15): 1158 - 1159. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Stanford, N. S. Weiss, L. F. Voigt, J. R. Daling, L. A. Habel, and M. A. Rossing Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-aged Women JAMA, July 12, 1995; 274(2): 137 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Colditz, S. E. Hankinson, D. J. Hunter, W. C. Willett, J. E. Manson, M. J. Stampfer, C. Hennekens, B. Rosner, and F. E. Speizer The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women N. Engl. J. Med., June 15, 1995; 332(24): 1589 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Steinberg and S. J. Smith Breast Cancer and Estrogen Therapy-Reply JAMA, October 5, 1994; 272(13): 1004 - 1005. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Cobleigh, R. F. Berris, T. Bush, N. E. Davidson, N. J. Robert, J. A. Sparano, D. C. Tormey, W. C. Wood, Breast Cancer Committees of the Eastern Cooperativ, R. F. Berris, et al. Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change JAMA, August 17, 1994; 272(7): 540 - 545. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Grady, S. M. Rubin, D. B. Petitti, C. S. Fox, D. Black, B. Ettinger, V. L. Ernster, and S. R. Cummings Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women Ann Intern Med, December 15, 1992; 117(12): 1016 - 1037. [Abstract] [PDF]
|
|
|
|
|
|
J. B. Henrich The Postmenopausal Estrogen/Breast Cancer Controversy JAMA, October 14, 1992; 268(14): 1900 - 1902. [Abstract] [PDF]
|
|